Safety Study of EF-022 in Adults With Recurrent Respiratory Papillomatosis (RRP)

Condition:   Recurrent Respiratory Papillomatosis Intervention:   Drug: EF-022 (Modified Vitamin D Binding Protein Macrophage Activator) Sponsor:   Efranat Ltd. Not yet recruiting - verified August 2016
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials